Men with diabetes mellitus are less likely to be diagnosed with prostate cancer (PCa). As diabetic men have lower serum PSA, it is unclear if this is due to lower PCa incidence or reflects detection bias from fewer PSA-triggered biopsies. To account for differential biopsy rates, we used multivariate regression to examine the link between diabetes and PCa risk in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, which required all subjects to undergo biopsy regardless of PSA. We further tested for interaction between diabetes and obesity. Diabetes status and body mass index (BMI) measurements were obtained at baseline. On multivariate analysis, diabetes was not associated with PCa risk (odds ratio (OR) 1.01, 95% confidence interval 0.79-1.30, P ¼ 0.92) or risk of low-or high-grade disease (all PX0.65). When stratified by obesity, diabetes was also not associated with PCa risk in any BMI category (all PX0.15). However, there was suggestion of effect modification by obesity for high-grade disease (P-interaction ¼ 0.053). Specifically, diabetes was associated with decreased risk of high-grade PCa in normal-weight men but increased risk in obese men (OR 0.35 vs 1.38). In the REDUCE trial, when all men underwent biopsy, diabetes was not associated with lower PCa risk, but rather equal risk of PCa, low-grade PCa and high-grade PCa.
Introduction
The association between diabetes mellitus and risk of prostate cancer (PCa) has been studied extensively since the 1970s. 1 However, despite more than 20 cohort and case-control studies examining this relationship, controversy still persists regarding the influence of diabetes on PCa development. Several studies reported decreased PCa risk among diabetics whereas others found either no protective effect or an elevated risk. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Two recent meta-analyses, one examining studies from 1971-2002 and the other extending this review to 2005, both concluded diabetes is inversely associated with PCa risk. 2, 3 However, only a minor risk reduction (RR ¼ 0.91, 95% confidence interval (CI) 0.86-0.96) was noted in the first meta-analysis whereas, in the second, diabetes appeared protective only among studies conducted after widespread adoption of PSA screening (RR ¼ 0.73, 95% CI 0.64-0.83). 3 Interestingly, for studies published before the PSA era, diabetes was not significantly associated with PCa risk (RR ¼ 0.94, 95% CI 0.85-1.03). 3 As diabetes lowers serum PSA, this discrepancy in findings from the pre-PSA and PSA eras suggests the inverse association between diabetes and PCa risk reported in recent studies may stem partly from an effect of lower serum PSA in diabetic men. 13, 14 Moreover, obesity, which often accompanies diabetes, also depresses PSA through hemodilution, and this may contribute to even lower PSA values in diabetics. [15] [16] [17] Specifically, as most PCa cases are detected on biopsy following an abnormal PSA screen, lower PSA in men with diabetes and possible co-morbid obesity may obscure true prostatic disease by triggering fewer biopsies and leading to artificially lower rates of PCa diagnosis.
In this study, we investigated the association between diabetes and PCa risk in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. The unique design of REDUCE required subjects to have on-study biopsies at 2 and 4 years regardless of serum PSA, thus minimizing the influence of this biomarker on PCa detection. 18 We also examined the association of diabetes with risk of low-or high-grade PCa. As an earlier report from our group suggested obesity modifies the effect of diabetes on PCa aggressiveness following radical prostatectomy, we explored if obesity likewise modifies the effect of diabetes on risk of PCa diagnosis. 19 Finally, as several studies showed time since diabetes onset influences PCa risk, possibly due to fluctuations in serum insulin, we investigated if the association between diabetes and PCa risk differed in the first vs second 2 years of REDUCE, which corresponds roughly with earlier-and later-stage diabetes, respectively.
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Materials and methods
Study population
Details of the REDUCE trial are described elsewhere. 18 In brief, REDUCE was a 4-year international, multicenter, double-blinded, placebo-controlled clinical trial investigating the effectiveness of 0.5 mg dutasteride daily vs placebo in reducing biopsy-detected PCa. Men aged 50-75 were eligible if they had serum PSA between 2.5 and 10 ng ml À1 (or 3.0 and 10 ng ml À1 for men older than 60 years) and a single 6-12 core biopsy within the past 6 months negative for PCa, high-grade intraepithelial neoplasia, or atypical small acinar proliferation. Men with past history of PCa or prostate surgery, current prostate volume 480 ml, or International Prostate Symptom Score 425 (or 420 for men on alpha-blocker therapy) were additionally excluded. Serum PSA was measured every 6 months. Prostate volume was determined by transrectal ultrasound at time of randomization. Repeat 10-core biopsies were obtained at 2 and 4 years regardless of PSA or digital rectal examination findings. Patients were also allowed to have studyindependent biopsies. Diabetes status was by self-report at enrollment whereas body mass index (BMI) was calculated using height and weight (kg m À2 ) measured at baseline. The primary end-point was diagnosis of PCa at any time during the 4-year period.
Diabetes status was available for all 8122 men in the REDUCE efficacy population. However, 1393 did not receive an on-study biopsy whereas an additional 302 lacked complete covariate data; these men were subsequently excluded. Excluded subjects did not differ from the remaining 6427 men in our cohort in age, PSA, abnormal digital rectal examination findings or prostate volume (all PX0.39). However, men in the excluded group were more likely to be diabetic, of black or other non-white race and assigned to dutasteride (all Pp0.02). Finally, there was suggestion of higher BMI among excluded men (median 27.1 vs 26.9 kg m À2 , P ¼ 0.057).
Statistical analysis
The association between diabetes and clinical characteristics was examined using Wilcoxon rank-sum and w 2 -tests for continuous and categorical variables, respectively. The relationship between diabetes and baseline serum PSA (log-transformed) was explored using multivariate linear regression adjusting for age (continuous), race, abnormal digital rectal examination findings, BMI (log-transformed, continuous) and prostate volume (log-transformed, continuous).
The association between diabetes and PCa risk was explored using multivariate logistic regression adjusting for age (continuous), race, study arm, abnormal digital rectal examination findings, PSA (log-transformed, continuous), BMI (log-transformed, continuous) and prostate volume (log-transformed, continuous). As REDUCE was an international trial, possible confounding by geographic region was explored through sub-analysis of only men from the United States. Findings did not differ between the US and complete international cohorts. Thus, the full cohort was used for our analysis and country was not included in our regression models. Metformin use was also not included in our models despite available data as only diabetics were prescribed this medication, meaning this term is collinear with diabetes.
Associations between diabetes and risk of low-or high-grade PCa (Gleason o7 vs X7, respectively) vs no cancer were tested via multinomial logistic regression adjusting for the above covariates. Effect modification by BMI was explored by stratifying subjects into normal weight, overweight and obese categories (BMI o25, 25-29.9, and X30 kg m
À2
, respectively) and testing for interaction by including diabetes, BMI and the crossproduct of these terms in our regression models. For tests of interaction, subjects within a particular BMI category were assigned the median BMI value for that group to mitigate influence from outliers.
Finally, as several studies have found differences in PCa risk for early-vs late-stage diabetes, we further separated our cohort into men diagnosed with PCa in the first vs second 2 years of REDUCE. 4, [8] [9] [10] As time since diabetes onset was not available and because diabetes status was recorded at baseline, stratifying in this manner approximated diabetes progression as all men diagnosed with PCa in the latter half of REDUCE would have been diabetic for at least two and, more likely, 4 years given most PCa cases were detected on the 4-year biopsy. All statistical analysis was performed using Stata v11.2 (StataCorp, College Station, TX, USA).
Results
Participant characteristics
Of the 6427 total men included in our analysis, 375 (6%) had diabetes at baseline. On average, diabetics were older, had higher BMI, and were more likely to be of black or other non-white race (all Pp0.003; Table 1 ). There were no differences between diabetic and nondiabetic men with regard to other clinical characteristics (all PX0.18; Table 1 ). Notably, on both univariate and multivariate analysis, diabetes was not significantly associated with lower serum PSA (multivariate-adjusted P ¼ 0.21).
Association of diabetes with PCa
Over the 4 years of REDUCE, 1470 cases of PCa were detected with 446 (30%) representing high-grade disease. Of the total PCa diagnoses, 88 (6%) were in diabetic men and 26 (30%) of these were high grade. On both univariate and multivariate analyses, we found no association between diabetes and risk of PCa overall or risk of either low-or high-grade disease (all PX0.65; Table 2 ).
Diabetes, obesity and prostate cancer risk C Wu et al When stratified by the study interval during which PCa was diagnosed, we found non-significant suggestions of increased overall PCa risk among diabetics in the first 2 years of REDUCE but lower risk in the second 2 years (multivariate-adjusted odds ratio (OR) 1.20 vs 0.74, all PX0.21; Table 2 ). This was also true for low-(multivariate-adjusted OR 1.28 vs 0.71, all PX0.14) and high-grade disease (multivariate-adjusted OR 1.02 vs 0.78, all PX0.53; Table 2 ), although, again, none of these associations were significant.
Effect modification by BMI
After stratifying into normal weight, overweight and obese men, we found on multivariate analysis diabetes was not associated with overall PCa risk in any BMI category (all PX0.32), and the interaction between diabetes and BMI was not significant (P-interaction ¼ 0.18; Table 3 ). Diabetes was not associated with risk of either low-or high-grade disease in any BMI category (all PX0.15; Table 3 ). Likewise, there was no significant interaction between diabetes and BMI for low-grade disease (P-interaction ¼ 0.60). However, there was suggestion that BMI modifies the effect of diabetes on risk of high-grade PCa (P-interaction ¼ 0.053). Specifically, diabetes may be associated with lower rates of high-grade disease in normal-weight men but higher rates in obese men (OR 0.35 vs 1.38; Table 3 ). However, neither of these observations approached statistical significance.
Discussion
As both type 1 and type 2 diabetes involve loss of insulin production from pancreatic b-islet cells, and as insulin is a potent mitogen, it has been postulated that the hypoinsulinemic state characterizing diabetes impairs cellular proliferation and confers protection against PCa. [20] [21] [22] Indeed, many studies have reported an inverse association between diabetes and PCa risk. [2] [3] [4] [5] [6] [7] [9] [10] [11] However, diabetes is also linked to lower serum PSA. 13, 14 Thus, in clinical practice where PSA screening drives recommendations for biopsy and, hence, PCa detection, an alternative explanation for the attenuated PCa risk reported by many but not all studies is that lower PSA in diabetics leads to fewer biopsies and, consequently, to less frequent diagnosis of extant cancer. In fact, the majority of studies linking diabetes to lower PCa risk have been published in the PSA era, with a recent meta-analysis reporting significantly lower PCa risk among diabetic men in studies published after but not before 1990. 3 Furthermore, as obesity also lowers serum PSA due to hemodilution, its frequent co-existence with diabetes may further impair PCa detection in diabetics. [15] [16] [17] To address this, we investigated the relationship between diabetes and PCa risk in the REDUCE trial. ). c As measured on pre-enrollment trans-rectal ultrasound study. Diabetes, obesity and prostate cancer risk C Wu et al
The unique design of REDUCE required that all participants undergo prostate biopsy regardless of serum PSA. 18 Thus, PSA testing did not serve as a gatekeeper to more definitive biopsy in REDUCE, allowing better examination of the true relationship between diabetes and PCa risk. However, as REDUCE imposed a lower PSA limit of 2.5 ng ml À1 , our analysis, although less susceptible to the effects of PSA, was not completely shielded from its influence. Specifically, as higher hemoglobin A1c (HbA1c) has been shown to correlate inversely with PSA, it is possible that our cohort was biased toward men with better-controlled diabetes, as men with poorly controlled diabetes may have had PSA values o2.5 ng ml À1 . 23 This may also explain why, in contrast to other studies, we did not find diabetes to predict lower serum PSA. 13, 14 However, the implications of this potential selection bias are unclear given only one study has examined the link between HbA1c and PCa risk, reporting an inverse association in men under age 59, although, presumably, as HbA1c increased, so did the degree of PSA depression and likelihood for underdiagnosis. 24 Under the unique conditions of the REDUCE trial, we found diabetes did not lower overall PCa risk, or risk of low-or high-grade disease. Our results are consistent with several earlier studies that also found no association but differ from more recent reports concluding diabetes to be protective. 1, [4] [5] [6] [7] [9] [10] [11] [12] One possible reason for our null findings and the inverse associations in previous studies is that PSA testing did not drive biopsies in REDUCE, thereby eliminating a source of detection bias potentially present in earlier studies. Indeed, such bias would explain the discrepancy in PCa risk estimates among studies conducted before and within the PSA era. 3 It may also explain findings linking both diabetes and elevated HbA1c to higher-grade tumors at biopsy and surgery. [25] [26] [27] Interestingly, several studies have reported increased PCa risk in the years immediately following diabetes onset but lower risk thereafter. 4, [8] [9] [10] This could be due to detection bias from more frequent health care encounters around the time of diagnosis or may reflect true biological disturbances. For instance, although type 2 diabetes leads eventually to hypoinsulinemia, insulin output actually increases during the initial phase of glucose intolerance. Additionally, expression of the protumor insulin-like growth factor (IGF)-1 is upregulated while expression of the anti-tumor IGF-1 binding protein (IGFBP)-3 is suppressed. [28] [29] [30] As pancreatic b-islet cell loss accelerates, insulin production declines, potentially yielding a protective effect later on. Thus, an alternative explanation for our null findings is that the REDUCE cohort is balanced with respect to diabetes progression and our results merely reflect cancelation of opposing risks. Indeed, after stratifying by study interval to approximate early-vs late-stage diabetes, we found a suggestion of higher PCa risk among diabetic men in the first 2 years of REDUCE but lower risk in the second two years. Although interesting, these observations are statistically not significant, and the degree to which they represent type I error is not known. Thus, they should be viewed with caution.
In contrast to our null findings, an analysis of 10 238 men who underwent end-of-study biopsy in the 7-year Prostate Cancer Prevention Trial (PCPT) found diabetes to significantly lower PCa risk (OR ¼ 0.66, 95% CI 0.52-0.83). 5 As PCPT was a longer trial than REDUCE and as all biopsies occurred at the end of the study, it is conceivable that PCPT included relatively more men with advanced diabetes. In fact, the PCPT results are consistent with a separate study reporting lower PCa risk at 5-10 years following diabetes onset (RR 0.66, 95% CI 0.39-1.10). 10 Additionally, many PCa cases in PCPT were diagnosed through for-cause biopsies, which was not true in REDUCE where only 7.5% of biopsies were study independent. 10 Finally, REDUCE was an international trial whereas PCPT enrolled only American subjects. However, geographical differences are unlikely to explain the disagreement in our findings as it persisted even after restricting analysis to the United States.
Previously, we found obesity modifies the effect of diabetes on risk of biochemical recurrence after radical prostatectomy, with diabetics having a more aggressive disease than non-diabetics, but only among obese white men. 19 In the current study, although we did not detect a significant interaction between obesity and diabetes on overall PCa risk, we did observe a near-significant trend for high-grade disease (P-interaction ¼ 0.053), with diabetes possibly conferring lower risk in normal-weight men but increased risk in obese men. In the single report so far to examine the influence of obesity on diabetes and PCa incidence, Gong, et al. 5 , did not find any significant interaction in PCPT. Our findings suggest that obesity may weakly modify the effect of diabetes on PCa risk, but only for high-grade disease. We caution, however, that the formal test of interaction between BMI and diabetes merely approached but did not meet statistical significance. Additional studies with greater power to detect small yet clinically important effects will be necessary to fully address this question, which, as the prevalence of both obesity and diabetes increases, will only grow in importance.
A limitation of our analysis was reliance on selfreported diabetes status; however, past studies have found 497% concordance between this information and Diabetes, obesity and prostate cancer risk C Wu et al actual disease. 31 Diabetic and non-diabetic groups also differed in several clinical characteristics. Although not uniform, our cohort nevertheless captured the known epidemiology of diabetes, with diabetics more likely to be older, heavier and of black race, and we further adjusted for these attributes in our regression models. 32 Additional limitations included lack of data on diabetes duration, which hampered our ability to stratify PCa risk by early-and late-stage diabetes, disorder type (although epidemiological data suggests 495% are likely type 2) and degree of glycemic control. 33 Finally, although insulin and oral hypoglycemic agents may independently influence PCa risk, it was not possible to adjust for these medications due to collinearity. 7, 34, 35 Herein, we sought to provide a global assessment of the importance of diabetes on PCa risk. Future analyses from REDUCE will focus on the role of medications specifically among diabetic men.
Despite these limitations, the key strength of REDUCE was the requirement that all participants undergo biopsy regardless of serum PSA, thereby minimizing the influence of this biomarker on PCa detection. Our study also included a large sample size, and all data used to calculate BMI were directly measured. Finally, as REDUCE was a large multi-center phase III clinical trial, study conduct was rigorously monitored to ensure maximum data quality.
In summary, in the REDUCE trial, when all men undergo biopsy regardless of serum PSA, diabetes was not associated with lower PCa risk, but rather equal risk of PCa overall and equal risk of low-and high-grade disease. Our findings suggest that lower rates of PCa previously observed in diabetics may stem, at least in part, from lower serum PSA leading to fewer biopsies and less frequent detection of disease. However, other explanations for these findings exist. Thus, additional studies are needed to confirm our results and clarify the degree, if any, to which lower serum PSA obscures PCa incidence in diabetic men. Our results also add to the limited body of literature examining the interplay between obesity, diabetes and PCa by suggesting that BMI may modify the effect of diabetes on risk of highgrade PCa. Given that many diabetic men are also obese, this is an important relationship that warrants further investigation.
